AKRX stock news

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half results and raised 2019 guidance) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 14) Acer Therapeutics Inc (NASDAQ: ACER ) (reacted to second-quarter results) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akorn, Inc. (NASDAQ: AKRX ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) aTyr Pharma Inc (NASDAQ: LIFE ) (reacted to second-quarter results) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cancer Genetics Inc (NASDAQ: CGIX ) Cellectis SA (NASDAQ: CLLS ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced $6.5 million common stock offering) DiaMedica Therapeutics Inc (NASDAQ: DMAC )(reacted to second-quarter results) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) GENFIT S A/ADR (NASDAQ: GNFT ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Medigus ADR (NASDAQ: MDGS ) Meridian Bioscience, Inc. Read more
The generic drugmaker Akorn is facing a world of trouble. The German healthcare giant Fresenius, which received court approval last year to walk away from a $4.75 billion deal to acquire Akorn, is suing Akorn in Delaware Chancery Court for damages from the busted deal. The U.S. Food and Drug Administration is investigating data integrity issues at the company’s manufacturing plants, issuing two warning letters this year about potential regulatory shortcomings. Akorn is also feeling pressure from its lenders. The company said in its most recently-filed quarterly financial statement that it’s working on a refinancing deal, but said that if those negotiations fail, Akorn faces a default that “could materially affect the company’s business, financial position and results of operations.” Read more
Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Generic pharmaceuticals manufacturer Akorn, Inc. (NASDAQ: AKRX) said Tuesday that it received a warning letter from the Food and Drug … Read more

95 Biggest Movers From Yesterday

05:01am, Thursday, 09'th May 2019
Gainers Corindus Vascular Robotics, Inc. (NYSE: CVRS) climbed 35.71 percent to close at $2.85 on Wednesday following Q1 results. Akorn, Inc. (NASDAQ: AKRX) … Read more

Akorn (AKRX) Q1 2019 Earnings Call Transcript

01:24pm, Wednesday, 08'th May 2019
AKRX earnings call for the period ending March 31, 2019. Read more

Akorn beats Q1 consensus

11:50am, Tuesday, 07'th May 2019
Read more

Akorn Q1 2019 Earnings Preview

09:30pm, Monday, 06'th May 2019
Akorn (NASDAQ:AKRX) is scheduled to announce Q1 earnings results on Tuesday, May 7th, before market open. The consensus EPS Estimate is -$0.17 and the cons Read more

Akorn Receives 2 Generic Nose Spray Approvals

01:28pm, Monday, 22'nd Apr 2019
Shares of specialty generic pharma company Akorn, Inc. (NASDAQ: AKRX ) are advancing solidly Monday morning thanks to twin announcements announced late last week. What Happened Akorn said the FDA greenlighted two of its generic candidates: 1) fluticasone propionate nasal spray USP, 50 mcg per spray and 2) loteprednol etabonate ophthalmic suspension, 0.5 percent. The fluticasone propionate nasal spray, indicated as a temporary relief for … Full story available on Benzinga.com Read more

Proudly made at